Cargando…

European Multicenter Study on Degradable Starch Microsphere TACE: The Digestible Way to Conquer HCC in Patients with High Tumor Burden

SIMPLE SUMMARY: In this European multicenter study, we investigated the treatment efficacy and safety of degradable starch microsphere transarterial chemoembolization (DSM-TACE) for HCC treatment in 121 patients in whom other standard therapies failed or patients were not eligible. Patients survived...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ludwig, Johannes M., Iezzi, Roberto, Theysohn, Jens M., Albrecht, Thomas, Posa, Alessandro, Gross, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533832/ https://www.ncbi.nlm.nih.gov/pubmed/34680272 http://dx.doi.org/10.3390/cancers13205122

Ejemplares similares

Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy
por: Schicho, Andreas, et al.
Publicado: (2017)

Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies
por: Schicho, Andreas, et al.
Publicado: (2018)

Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study
por: Gruber-Rouh, Tatjana, et al.
Publicado: (2018)

Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9
por: Minici, Roberto, et al.
Publicado: (2021)

Repeated Transarterial Chemoembolization with Degradable Starch  Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study
por: Orlacchio, Antonio, et al.
Publicado: (2018)

Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: results from a multicenter study
por: Müller, Lukas, et al.
Publicado: (2022)

Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC): Results from a National Multi-Center Study on Safety and Efficacy
por: Schicho, Andreas, et al.
Publicado: (2017)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
por: Fan, Wenzhe, et al.
Publicado: (2021)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study
por: Fan, Wenzhe, et al.
Publicado: (2022)

COCH predicts survival and adjuvant TACE response in patients with HCC
por: Wang, Chen, et al.
Publicado: (2021)

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
por: Huang, Wei, et al.
Publicado: (2022)

Lenvatinib resistance mechanism and potential ways to conquer
por: Bo, Wentao, et al.
Publicado: (2023)

The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT
por: Sun, HongLiang, et al.
Publicado: (2017)

Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020)

CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
por: Kinzler, Maximilian N., et al.
Publicado: (2023)

Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China
por: Wu, Zhao, et al.
Publicado: (2023)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
por: Wang, Wei‐Jun, et al.
Publicado: (2023)

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
por: Bargellini, Irene, et al.
Publicado: (2021)

Published trials of TACE for HCC are often not registered and subject to outcome reporting bias
por: Grégory, Jules, et al.
Publicado: (2020)

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
por: Sun, Tao, et al.
Publicado: (2023)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

Reversible occlusion of the pulmonary vasculature by transarterial embolisation with degradable starch microspheres: preclinical assessment in a human isolated lung perfusion model
por: Schaarschmidt, Benedikt M., et al.
Publicado: (2022)

Intravital Microscopic Research of Microembolization with Degradable Starch Microspheres
por: Ebert, Micaela, et al.
Publicado: (2013)

Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
por: Zhu, Yejing, et al.
Publicado: (2023)

Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
por: Scartozzi, Mario, et al.
Publicado: (2010)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center
por: Luz, Jose Hugo Mendes, et al.
Publicado: (2017)

Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features
por: Li, Zhi-Wei, et al.
Publicado: (2022)

Prognostic value of des-γ-carboxyprothrombin in patients with AFP-negative HCC treated with TACE
por: Sun, Hanyao, et al.
Publicado: (2022)

Pain after thoracotomy: Conquered or to be conquered?
por: Singariya, Geeta, et al.
Publicado: (2023)

Workarounds that work: how to conquer anything that stands in your way at work
por: Bishop, Russell
Publicado: (2011)

Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis
por: Guo, Tao, et al.
Publicado: (2018)

Effects of TACE combined with precise RT on p53 gene expression and prognosis of HCC patients
por: Liu, Yupeng, et al.
Publicado: (2018)

Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients
por: Jiang, Bei-Ge, et al.
Publicado: (2017)

The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE
por: Lim, Jihye, et al.
Publicado: (2021)

Quantitative assessment of HCC wash-out on CT is a predictor of early complete response to TACE
por: Fronda, Marco, et al.
Publicado: (2021)

Repeated TACE in HCC after Fontan surgery and situs viscerum inversus: A case report
por: Gasparrini, Fulvio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dfcgsmjk6hqedg1pa3gv5ab2bf